STOCK TITAN

[Form 4] CeriBell, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Ceribell, Inc. (CBLL) insider Scott Blumberg, who is Chief Financial Officer and a director, reported a disposition of 687 shares of common stock on 08/25/2025 at a price of $11.58 per share. After the reported sale, Mr. Blumberg beneficially owned 119,374 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025. The filing lists no derivative transactions or additional explanations.

Ceribell, Inc. (CBLL) insider Scott Blumberg, che ricopre il ruolo di Chief Financial Officer e di direttore, ha riportato la vendita di 687 azioni ordinarie in data 08/25/2025 al prezzo di $11.58 per azione. Dopo la vendita segnalata, il Sig. Blumberg deteneva beneficiariamente 119,374 azioni. Il Modello 4 è stato firmato da un mandatario il 08/27/2025. La segnalazione non indica operazioni su strumenti derivati né fornisce ulteriori spiegazioni.

El insider de Ceribell, Inc. (CBLL), Scott Blumberg, quien es Chief Financial Officer y director, informó la enajenación de 687 acciones ordinarias el 08/25/2025 a un precio de $11.58 por acción. Tras la venta informada, el Sr. Blumberg poseía beneficiariamente 119,374 acciones. El Formulario 4 fue firmado por un apoderado el 08/27/2025. La presentación no incluye transacciones con derivados ni explicaciones adicionales.

Ceribell, Inc. (CBLL)의 내부자이자 최고재무책임자 겸 이사인 Scott Blumberg는 08/25/2025에 보통주 687주를 주당 $11.58에 처분했다고 보고했습니다. 보고된 매도 후 Blumberg 씨는 실질적으로 119,374주를 보유하고 있었습니다. Form 4는 08/27/2025에 대리인이 서명했습니다. 제출서에는 파생상품 거래나 추가 설명이 기재되어 있지 않습니다.

L'initié de Ceribell, Inc. (CBLL), Scott Blumberg, qui est Chief Financial Officer et administrateur, a déclaré une cession de 687 actions ordinaires le 08/25/2025 au prix de $11.58 par action. Après la vente signalée, M. Blumberg détenait à titre bénéficiaire 119,374 actions. Le Formulaire 4 a été signé par un mandataire le 08/27/2025. Le dépôt ne mentionne aucune transaction sur dérivés ni explication supplémentaire.

Der Insider von Ceribell, Inc. (CBLL), Scott Blumberg, der als Chief Financial Officer und Direktor tätig ist, meldete die Veräußerung von 687 Aktien des Stammkapitals am 08/25/2025 zu einem Preis von $11.58 je Aktie. Nach dem gemeldeten Verkauf hielt Herr Blumberg wirtschaftlich 119,374 Aktien. Das Formular 4 wurde am 08/27/2025 von einem Bevollmächtigten unterzeichnet. Die Meldung listet keine Derivatgeschäfte oder weitere Erläuterungen auf.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine small insider sale; no derivatives or other transactions reported.

The Form 4 documents a single non-derivative disposition of 687 shares at $11.58, leaving the reporting person with 119,374 shares. This is a straightforward disclosure required under Section 16; the filing contains no indication of planned trading programs or derivative activity. The transaction is clearly reported and properly executed by an attorney-in-fact, meeting filing formalities.

TL;DR: Compliance-focused filing showing an officer/director sale; appears procedurally complete.

The report names Scott Blumberg as CFO and director and shows a single sale recorded with signature by an attorney-in-fact. The form includes the required ownership post-transaction and lacks any supplemental explanations or indicators of Rule 10b5-1 plans. From a governance and disclosure perspective, the filing fulfills statutory reporting requirements without additional detail.

Ceribell, Inc. (CBLL) insider Scott Blumberg, che ricopre il ruolo di Chief Financial Officer e di direttore, ha riportato la vendita di 687 azioni ordinarie in data 08/25/2025 al prezzo di $11.58 per azione. Dopo la vendita segnalata, il Sig. Blumberg deteneva beneficiariamente 119,374 azioni. Il Modello 4 è stato firmato da un mandatario il 08/27/2025. La segnalazione non indica operazioni su strumenti derivati né fornisce ulteriori spiegazioni.

El insider de Ceribell, Inc. (CBLL), Scott Blumberg, quien es Chief Financial Officer y director, informó la enajenación de 687 acciones ordinarias el 08/25/2025 a un precio de $11.58 por acción. Tras la venta informada, el Sr. Blumberg poseía beneficiariamente 119,374 acciones. El Formulario 4 fue firmado por un apoderado el 08/27/2025. La presentación no incluye transacciones con derivados ni explicaciones adicionales.

Ceribell, Inc. (CBLL)의 내부자이자 최고재무책임자 겸 이사인 Scott Blumberg는 08/25/2025에 보통주 687주를 주당 $11.58에 처분했다고 보고했습니다. 보고된 매도 후 Blumberg 씨는 실질적으로 119,374주를 보유하고 있었습니다. Form 4는 08/27/2025에 대리인이 서명했습니다. 제출서에는 파생상품 거래나 추가 설명이 기재되어 있지 않습니다.

L'initié de Ceribell, Inc. (CBLL), Scott Blumberg, qui est Chief Financial Officer et administrateur, a déclaré une cession de 687 actions ordinaires le 08/25/2025 au prix de $11.58 par action. Après la vente signalée, M. Blumberg détenait à titre bénéficiaire 119,374 actions. Le Formulaire 4 a été signé par un mandataire le 08/27/2025. Le dépôt ne mentionne aucune transaction sur dérivés ni explication supplémentaire.

Der Insider von Ceribell, Inc. (CBLL), Scott Blumberg, der als Chief Financial Officer und Direktor tätig ist, meldete die Veräußerung von 687 Aktien des Stammkapitals am 08/25/2025 zu einem Preis von $11.58 je Aktie. Nach dem gemeldeten Verkauf hielt Herr Blumberg wirtschaftlich 119,374 Aktien. Das Formular 4 wurde am 08/27/2025 von einem Bevollmächtigten unterzeichnet. Die Meldung listet keine Derivatgeschäfte oder weitere Erläuterungen auf.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Blumberg Scott

(Last) (First) (Middle)
C/O CERIBELL, INC.
360 N. PASTORIA AVENUE

(Street)
SUNNYVALE CA 94085

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Ceribell, Inc. [ CBLL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/25/2025 F 687 D $11.58 119,374 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Louisa Daniels, Attorney-in-Fact for Scott Blumberg 08/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Scott Blumberg report on Form 4 for CBLL?

The Form 4 reports a disposition of 687 shares of Ceribell common stock on 08/25/2025 at $11.58 per share.

How many Ceribell (CBLL) shares does the reporting person own after the sale?

After the reported transaction, Scott Blumberg beneficially owned 119,374 shares.

What is Scott Blumberg's role at Ceribell as listed on the Form 4?

The Form 4 lists Scott Blumberg as a Director and the company's Chief Financial Officer.

Was a derivative transaction or Rule 10b5-1 plan disclosed in this Form 4?

No derivatives or any indication of a Rule 10b5-1 trading plan are disclosed in the form.

Who signed the Form 4 for Scott Blumberg and when?

The Form 4 was signed by Louisa Daniels, Attorney-in-Fact for Scott Blumberg on 08/27/2025.
CeriBell, Inc.

NASDAQ:CBLL

CBLL Rankings

CBLL Latest News

CBLL Latest SEC Filings

CBLL Stock Data

419.44M
28.88M
10.39%
84.32%
3.46%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
SUNNYVALE